Physician profile
Barry Dean Stringfield
NPI 1225111743
$988.95
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2024: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $196.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $208.14 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $161.15 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $116.60 | 2019-2024 | Mounjaro |
| Abbvie INC. | $114.97 | 2019 | |
| Novo Nordisk INC | $112.95 | 2019 | |
| Biodelivery Sciences International, INC. | $97.86 | 2019 | |
| Ucb, INC. | $38.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.72 | 2019 | |
| Janssen Biotech, INC. | $24.60 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.04 | 2019 | |
| Genentech USA, INC. | $13.03 | 2019 | |
| Pfizer INC. | $12.92 | 2019 | |
| Glaxosmithkline, LLC. | $12.29 | 2019 | |
| Forte Bio-Pharma LLC | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Stringfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.